Focus Biotech

Focus Biotech is a clinical-stage biotechnology company headquartered in Beijing, China, dedicated to the discovery and development of innovative small molecule therapeutics for oncology and autoimmune disorders. The company's research focus centers on the modulation of the immune system by targeting key kinases and pathways within the tumor microenvironment. Its lead clinical candidate, FB-101, is a potent and selective inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1), currently being evaluated in Phase 1 clinical trials for patients with advanced solid tumors. By utilizing advanced medicinal chemistry and deep immunological insights, Focus Biotech aims to develop next-generation therapies that can overcome resistance to current checkpoint inhibitors. The company is backed by prominent venture capital firms and continues to expand its pipeline of targeted immuno-oncology programs.